It's a precursor to other vital antioxidants like glutathione
Gastrointestinal symptoms beyond nausea warrant detailed tracking
Review our guide on weight loss stalls for systematic troubleshooting
The SELECT trial showed that semaglutide reduced major adverse cardiovascular events (heart attack, stroke, cardiovascular death) in adults with obesity and established cardiovascular disease, without requiring a diabetes diagnosis. The FLOW trial showed kidney benefits with semaglutide use in patients with type 2 diabetes and chronic kidney disease. Improvements in hard clinical outcomes like cardiac events, kidney disease, and death are commonly observed with GLP-1 use, and are due to both the direct effects of treating the obesity, and indirect effects of the medications themselves
the mechanisms by which saponins modulate the immune system in combination with chemotherapy require further validation in tumor models
The exact reason is unknown, and researchers need to conduct more studies